Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic model

ConclusionsThe addition of either fosfomycin or tobramycin to ceftolozane/tazobactam at simulated human clinically observed concentrations reducedP. aeruginosa bacterial loads and the risk of resistance to ceftolozane/tazobactam when strains had ceftolozane/tazobactam MIC values at or above the clinical breakpoint.
Source: Journal of Antimicrobial Chemotherapy - Category: Microbiology Source Type: research